NASDAQ : GRFS
Grifols, S.A. — Key statistics
Healthcare · Drug Manufacturers - General · Spain
Last price 8.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.30B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.30B |
| Enterprise Value | 19.86B |
Dates
| Measure | Value |
|---|
| Earnings Date | Jul 28, 2022 |
| Ex-Dividend Date | Jul 2, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 680.58M |
| Shares Change (YoY) | +4.17% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 50.51% |
| Float | 418.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 21.88 |
| Forward PE | 9.88 |
| PS Ratio | 0.86 |
| Forward PS | 1.57 |
| PB Ratio | 0.80 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.96 |
| P/OCF Ratio | 5.96 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 38.46 |
| EV / Sales | 2.34 |
| EV / EBITDA | 10.57 |
| EV / EBIT | 12.89 |
| EV / FCF | 21.67 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.37 |
| Quick Ratio | 0.70 |
| Debt / Equity | 1.17 |
| Debt / EBITDA | 5.42 |
| Debt / FCF | 11.66 |
| Interest Coverage | 2.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 6.93% |
| Return on Assets (ROA) | 4.23% |
| Return on Invested Capital (ROIC) | 6.49% |
| Return on Capital Employed (ROCE) | 7.56% |
| Weighted Average Cost of Capital (WACC) | 7.52% |
| Revenue Per Employee | $339,129 |
| Profits Per Employee | $20,656 |
| Employee Count | 25,000 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 1.35 |
Taxes
| Measure | Value |
|---|
| Income Tax | 146.24M |
| Effective Tax Rate | 19.16% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.20 |
| 52-Week Price Change | -13.74% |
| 50-Day Moving Average | 7.59 |
| 200-Day Moving Average | 8.00 |
| Relative Strength Index (RSI) | 66.73 |
| Average Volume (20 Days) | 607,659 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.99M |
| Short Previous Month | 7.00M |
| Short % of Shares Out | 0.40% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 11.06 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 8.48B |
| Gross Profit | 3.20B |
| Operating Income | 1.54B |
| Pretax Income | 763.17M |
| Net Income | 516.39M |
| EBITDA | 1.88B |
| EBIT | 1.54B |
| Earnings Per Share (EPS) | $0.37 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 613.50M |
| Total Debt | 10.69B |
| Net Cash | -10.08B |
| Net Cash Per Share | -$14.80 |
| Equity (Book Value) | 9.12B |
| Book Value Per Share | 9.31 |
| Working Capital | 3.51B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.22B |
| Capital Expenditures | -307.37M |
| Depreciation & Amortization | 332.05M |
| Net Borrowing | -602.40M |
| Free Cash Flow | 916.50M |
| FCF Per Share | $1.35 |
Margins
| Measure | Value |
|---|
| Gross Margin | 37.79% |
| Operating Margin | 18.18% |
| Pretax Margin | 9.00% |
| Profit Margin | 6.09% |
| EBITDA Margin | 22.17% |
| EBIT Margin | 18.18% |
| FCF Margin | 11.01% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.11 |
| Dividend Yield | 1.31% |
| Dividend Growth (YoY) | -39.80% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 14.39% |
| FCF Payout Ratio | 7.91% |
| Buyback Yield | -4.17% |
| Shareholder Yield | -2.86% |
| Earnings Yield | 4.57% |
| FCF Yield | 12.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.37 |
| Price Target Difference | 28.03% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 4.59% |
| EPS Growth Forecast (3Y) | 26.54% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 4, 2016 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.12 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |